Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (AU2016375566) Polymorphic crystalline forms of obeticholic acid

Office : Australia
Application Number: 2016375566 Application Date: 08.01.2016
Publication Number: 2016375566 Publication Date: 29.06.2017
Publication Kind : A1
Prior PCT appl.: Application Number:US2016012651 ; Publication Number: Click to see the data
IPC:
C07J 9/00
A61K 31/575
A61P 1/16
C07J 17/00
C07J 51/00
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
J
STEROIDS
9
Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
56
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
575
substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1
Drugs for disorders of the alimentary tract or the digestive system
16
for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
J
STEROIDS
17
Normal steroids containing carbon, hydrogen, halogen, or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta[a]hydrophenanthrene skeleton
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
J
STEROIDS
51
Normal steroids with unmodified cyclopenta[a]hydrophenanthrene skeleton not provided for in groups C07J1/-C07J43/151
Applicants: Intercept Pharmaceuticals, Inc.
Inventors:
Agents: Spruson & Ferguson
Priority Data: 14/979,005 22.12.2015 US
Title: (EN) Polymorphic crystalline forms of obeticholic acid
Abstract: front page image
(EN) The present application relates to crystalline forms A, D, F, G and I of obeticholic acid. These crystalline forms are useful in the production of Obeticholic acid (in particular its purification), which is a drug useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.
Also published as:
CA3009149MYPI 2018000967IL259998SG11201805235XKR1020180095070CN108495858
EP3394081MX2018007776BR112018012590EA201891491PH1/2018/501318ID2019/01700
WO/2017/111979